Details

Autor(en) / Beteiligte

• Maris, John M
• Mosse, Yael P
• Bradfield, Jonathan P
• Hou, Cuiping
• Monni, Stefano
• Scott, Richard H
• Asgharzadeh, Shahab
• Attiyeh, Edward F
• Diskin, Sharon J
• Laudenslager, Marci
• Winter, Cynthia
• Cole, Kristina A
• Glessner, Joseph T
• Kim, Cecilia
• Frackelton, Edward C
• Casalunovo, Tracy
• Eckert, Andrew W
• Capasso, Mario
• Rappaport, Eric F
• McConville, Carmel
• London, Wendy B
• Seeger, Robert C
• Rahman, Nazneen
• Devoto, Marcella
• Grant, Struan F.A
• Li, Hongzhe
• Hakonarson, Hakon

Titel

Chromosome 6p22 Locus Associated with Clinically Aggressive Neuroblastoma

Ist Teil von

• The New England journal of medicine, 2008-06, Vol.358 (24), p.2585-2593

Ort / Verlag

Boston, MA: Massachusetts Medical Society

Erscheinungsjahr

2008

Quelle

Free E-Journal (出版社公開部分のみ）

Beschreibungen/Notizen

• Somatic characteristics of neuroblastoma tumors — such as MYCN amplification — are associated with more aggressive disease. This report shows that persons who inherit variants on chromosome 6p22 are more susceptible to the development of the disease than those who do not inherit these variants. This report shows that persons who inherit variants on chromosome 6p22 are more susceptible to the development of neuroblastoma than those who do not inherit these variants. Despite marked improvements in the cure rates for many childhood cancers, neuroblastoma remains an important clinical problem, accounting for 15% of the deaths attributable to malignant conditions in children. 1 It is the most common solid cancer of early childhood, and approximately half of all patients with neuroblastoma present with widely disseminated disease that is often refractory to intensive chemoradiotherapy. Cure rates among these high-risk patients remain less than 40%, despite dramatic increases in the intensity of chemoradiotherapy, and survivors often have serious lifelong coexisting conditions. 2 – 4 Somatically acquired genomic aberrations in neuroblastoma are of fundamental importance for predicting the tumor . . .